![Dan Iazzetti](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dan Iazzetti
Human Resources Officer at ORIC PHARMACEUTICALS, INC.
Dan Iazzetti active positions
Companies | Position | Start | End |
---|---|---|---|
ORIC PHARMACEUTICALS, INC. | Human Resources Officer | 2022-08-31 | - |
Career history of Dan Iazzetti
Former positions of Dan Iazzetti
Companies | Position | Start | End |
---|---|---|---|
FIVE PRIME THERAPEUTICS, INC. | Human Resources Officer | - | - |
ANGN BIOM | Human Resources Officer | - | - |
Training of Dan Iazzetti
Marist College | Undergraduate Degree |
Statistics
International
United States | 5 |
Operational
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ORIC PHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
Angion Biomedica Corp.
![]() Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA. | Health Technology |
Five Prime Therapeutics, Inc.
![]() Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Stock Market
- Insiders
- Dan Iazzetti
- Experience